Indication : For the Management of Dyslipidemia
Dyslipidemia a condition characterized by an abnormal level of lipids (such as cholesterol, triglycerides, LDL, and HDL) in the blood, which can increase the risk of cardiovascular disease, including heart attacks, strokes, and peripheral artery disease.
MOA : Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts -3-hydroxy-3- methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol. Aspirin is inhibitory of Thromboxane A2 and COX inhibitory. Clopidogrel Inhibits platelet activation and aggregation by irreversibly binding to P2Y12 receptor on platelets.
